BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 23973201)

  • 1. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
    Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
    Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
    Iranzo V; Sirera R; Bremnes RM; Blasco A; Jantus-Lewintre E; Tarón M; Berrocal A; Blasco S; Caballero C; Del Pozo N; Rosell R; Camps C
    Clin Lung Cancer; 2011 Jul; 12(4):224-30. PubMed ID: 21726821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
    Su D; Ma S; Liu P; Jiang Z; Lv W; Zhang Y; Deng Q; Smith S; Yu H
    Lung Cancer; 2007 May; 56(2):281-8. PubMed ID: 17222938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
    Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
    Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.
    Pallaud C; Reck M; Juhasz E; Szima B; Yu CJ; Burdaeva O; Orlov S; Hilton M; Archer V; Mok T
    Lung Cancer; 2014 Oct; 86(1):67-72. PubMed ID: 25154982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
    Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
    Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis.
    Dong J; Hu Z; Shu Y; Pan S; Chen W; Wang Y; Hu L; Jiang Y; Dai J; Ma H; Jin G; Shen H
    Mol Carcinog; 2012 Jul; 51(7):546-52. PubMed ID: 21739480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
    Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
    Hong MJ; Lee SY; Choi JE; Jin CC; Kang HJ; Baek SA; Lee SY; Shin KM; Jeong JY; Lee WK; Yoo SS; Lee J; Cha SI; Kim CH; Son JW; Park JY
    Oncotarget; 2016 Mar; 7(13):15948-58. PubMed ID: 26893365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
    Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
    J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
    Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
    Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Sato Y; Yamamoto N; Kunitoh H; Ohe Y; Minami H; Laird NM; Katori N; Saito Y; Ohnami S; Sakamoto H; Sawada J; Saijo N; Yoshida T; Tamura T
    J Thorac Oncol; 2011 Jan; 6(1):132-8. PubMed ID: 21079520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients.
    Wang S; Wang J; Bai Y; Wang Q; Liu L; Zhang K; Hong X; Deng Q; Zhang X; He M; Wu T; Xu P; Guo H
    Cancer Med; 2016 Sep; 5(9):2332-42. PubMed ID: 27465648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Jung DK; Choi JE; Jin CC; Hong MJ; Do SK; Kang HG; Lee WK; Seok Y; Lee EB; Jeong JY; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Sci Rep; 2016 May; 6():25952. PubMed ID: 27181838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.